title: Reduced CXCR4 expression is associated with extramedullary disease in a mouse model of myeloma and predicts poor survival in multiple myeloma patients treated with bortezomib.
authors.affiliation: Department of Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, MN, USA.
authors.forename: H A F
authors.initials: HA
authors.lastname: Stessman
authors.forename: A
authors.initials: A
authors.lastname: Mansoor
authors.forename: F
authors.initials: F
authors.lastname: Zhan
authors.forename: S
authors.initials: S
authors.lastname: Janz
authors.forename: M A
authors.initials: MA
authors.lastname: Linden
authors.forename: L B
authors.initials: LB
authors.lastname: Baughn
authors.forename: B
authors.initials: B
authors.lastname: Van Ness
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D004195:Disease Models, Animal; D019008:Drug Resistance, Neoplasm; D005434:Flow Cytometry; D006801:Humans; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D011379:Prognosis; D011719:Pyrazines / Q000627:therapeutic use*; D019718:Receptors, CXCR4 / Q000378:metabolism*; D023981:Sarcoma, Myeloid / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality*; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D019718:Receptors, CXCR4; D000069286:Bortezomib